Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2009 Jun 11;360(24):2503-15. doi: 10.1056/NEJMoa0805796. Epub 2009 Jun 7.

A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Collaborators (433)

Detre KM, Kelsey SF, Brooks MM, Orchard TJ, Thomas SB, Tyrrell KS, Rana JS, Averbach F, MacGregor JM, O'Neal SM, Pitluga K, Sansing V, Tranchine M, Crow SW, Bertolet MM, Hardison R, Kip K, Lombardero M, Lu J, Janiszewski S, Protivnak D, Reiser S, Barton S, Guo P, Kushner Y, Michael O, Martin JP, Kania C, Kania M, O'Donnell J, Maxwell RA, Frye RL, Goldberg S, Rosenberg Y, Desvigne-Nickens P, Ershow A, Gordon D, Paltoo D, Jones TL, Hueb W, Ramires J, Lopes N, Wajchenberg BL, Martinez EE, Oliveira SA, Ribeiro EE, Perin M, Betti R, Schwartz L, Steiner G, Barolet A, Groenewoud Y, Mighton L, Camelon K, O'Rourke R, Blodgett J, Sako E, Nicastro J, Prescott R, Rihal C, Kennedy F, Barsness G, Basu A, Clavell A, Frye R, Holmes DR Jr, Lerman A, Mullaney C, Reeder G, Rizza R, Schaff H, Smith S, Somers V, Sundt T, Ting H, Wright RS, Helgemoe P, Lesmeister D, Rolbiecki D, Lepe-Montoya L, Escobedo J, Barraza R, Baleón R, Campos A, García P, Lezama C, Miramontes C, Ocampo S, Peñafiel JV, Valdespino A, Verdín R, Albarrán H, Ayala F, Chávez E, Murillo H, Buitrón LV, Rico-Verdin B, Angulo F, Adler D, Halle AA, Ismail-Beigi F, Paranjape S, Mazzurco S, Ridley K, Ramanathan K, Solomon S, Wall B, Weinman D, Touchstone T, Douglas L, Bourassa M, Tardif JC, Chiasson JL, Lavoie MA, Rabasa-Lhoret R, Langelier H, Foucher S, Trudel J, Monrad S, Srinivas V, Zonszein J, Crandall J, Duffy H, Vartolomei E, King S 3rd, Jacobs C, Robertson D, Porter M, Eley M, Nichols E, LaCorte J, Mock M, Rogers W, Ovalle F, Bell D, Misra VK, Hillegass WB, Aqel R, Pierce P, Smith M, Saag L, Vaughn A, Smith D, Grimes T, Rolli S, Hill R, Barrett BD, Morehead C, Doss K, Davidson CJ, Molitch M, Beohar N, Massaro E, Goodreau L, Arroyo F, Neuzil P, Pavlickova L, Stehlíková S, Benedik J, Coling L, Davies R, Glover C, LeMay M, Mesana T, Ooi TC, Silverman M, Sorisky A, Favreau C, McClinton S, Weiss M, Weiss I, Saulle L, Kannam H, Kurylas JC, Vasi L, Douglas J Jr, Ghazzal Z, Sperling L, King S 3rd, Dayamani P, Gebhart S, Basu S, Helmy T, Tangpricha V, Hyde P, Jenkins M, Grant BP, Kent K, Suddath W, Magee M, Julien-Williams P, Reed V, Nassar C, Dagenais G, Garceau C, Auger D, Buller C, Elliott T, Ramanathan K, Ricci D, Fox R, Kolesniak D, Attubato M, Feit F, Richardson S, Sing IP, Slater J, Amendola A, Vargas B, Tsapatsaris N, Woods B, Cushing G, Rutter M, Singh P, DesRochers G, Woodhead G, Gannon D, Campbell NS, Ragosta M, Sarembock I, Powers E, Barrett E, Jahn L, Murie K, Das G, Sigurdsson G, White C, Bantle J, Redmon JB, Kwong C, Tamis-Holland J, Albu J, Hochman JS, Slater J, Wilentz J, Frances S, Tormey D, Pepine C, Smith K, Kennedy L, Brezner K, Curry T, Bleyer F, Albert S, Mooradian A, Plummer S, Fuentes F, Robles R, Lavis V, Gomez J, Iliescu C, Underwood C, Fulton MS, Ramirez JG, Merta J, Scott G, Krishnaswami A, Dowdell L, Berkheimer S, Greenbaum A, Whitehouse F, Pangilinan R, Mann K, Jacobs AK, Sternthal E, Ebner S, Nedeljkovic Z, Beardsley P, Schneider D, Pratley R, Cefalu W, Schnure J, Rowen M, Tilton L, Niederman A, Mata C, Kellerman T, Farmer J, Garber AJ, Kleiman N, Howard N, Nichols D, Pool M, Granger C, Feinglos M, Adams G, Green J, Druken B, Underwood D, Stafford JL, Donner T, Laskey W, Beach D, Lopez J, Davis A, Faxon D, Reutrakul S, Bayer E, Marroquin O, Cohen H, Korytkowski M, Koerbel G, Baxendell L, Rosenfelder D, DeRiso L, Farrell C, Vita T, McGill J, Krone R, Bach R, Recklein C, Luepke KM, Clifton MJ, Farkouh ME, Kim MC, Smith DA, Guzman I, Travis A, O'Keefe J, Forker A, Isley W, Moe R, Kennedy P, Rosson M, Long A, Bates E, Herman W, Pop-Busui R, Duvernoy C, Stevens M, Luciano A, Majors C, Gottlieb SH, Rodriguez A, Herr M, Williams D, Smith RJ, Abbott JD, Laufgraben MJ, Grogan M, Muratori J, Habib G, Marcelli M, Mikati I, Cordero E, Caldwell G, Schechter D, Lorber D, August P, Brown M, Depree P, Huber K, Hanusch-Enserer U, Jordanova N, Cilesiz D, Vogel B, McCallister B Jr, Kleerekoper M, Mandagere K, Urbanic R, Bengston J, Kong BK, Pruitt A, Sanfield J, Carulli C, Churley-Strom R, Magorien R, Osei K, Boyer CC, Lee R, Palumbo P, Wisbey J, Alderman E, Ikeno F, Schwarzkopf A, Steffes M, Nowicki M, Bucksa J, Chaitman B, Eckstein J, Stocke K, Hlatky MA, Boothroyd DB, Melsop KA, Sobel BE, Rowen M, Neimane D, Iskandrian AE, Schaaf MB, Genuth S, Bongarno T, Nesto R, August P, Hultberg K, Gottlieb SH, Albu J, Rosenhouse-Romeo H, Orchard TJ, Pambianco G, Lombardero M, Mock M, Frye RL, Brooks MM, Desvigne-Nickens P, Ershow A, Genuth S, Goldberg S, Gordon D, Hardison R, Jones TL, Kelsey S, Nesto R, Orchard T, Paltoo D, Rosenberg Y, Ryan T, Lebovitz H, Brown R, Friesinger G, Horton E, Mason J, Virmani R, Wechsler L, Bairey-Merz CN, Kennedy JW, Gordon D, Antman E, Colwell J, Fowler S, Furberg C, Goldman L, Jennings B, Rankin S.

Abstract

BACKGROUND:

Optimal treatment for patients with both type 2 diabetes mellitus and stable ischemic heart disease has not been established.

METHODS:

We randomly assigned 2368 patients with both type 2 diabetes and heart disease to undergo either prompt revascularization with intensive medical therapy or intensive medical therapy alone and to undergo either insulin-sensitization or insulin-provision therapy. Primary end points were the rate of death and a composite of death, myocardial infarction, or stroke (major cardiovascular events). Randomization was stratified according to the choice of percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) as the more appropriate intervention.

RESULTS:

At 5 years, rates of survival did not differ significantly between the revascularization group (88.3%) and the medical-therapy group (87.8%, P=0.97) or between the insulin-sensitization group (88.2%) and the insulin-provision group (87.9%, P=0.89). The rates of freedom from major cardiovascular events also did not differ significantly among the groups: 77.2% in the revascularization group and 75.9% in the medical-treatment group (P=0.70) and 77.7% in the insulin-sensitization group and 75.4% in the insulin-provision group (P=0.13). In the PCI stratum, there was no significant difference in primary end points between the revascularization group and the medical-therapy group. In the CABG stratum, the rate of major cardiovascular events was significantly lower in the revascularization group (22.4%) than in the medical-therapy group (30.5%, P=0.01; P=0.002 for interaction between stratum and study group). Adverse events and serious adverse events were generally similar among the groups, although severe hypoglycemia was more frequent in the insulin-provision group (9.2%) than in the insulin-sensitization group (5.9%, P=0.003).

CONCLUSIONS:

Overall, there was no significant difference in the rates of death and major cardiovascular events between patients undergoing prompt revascularization and those undergoing medical therapy or between strategies of insulin sensitization and insulin provision. (ClinicalTrials.gov number, NCT00006305.)

2009 Massachusetts Medical Society

Comment in

PMID:
19502645
[PubMed - indexed for MEDLINE]
PMCID:
PMC2863990
Free PMC Article

Images from this publication.See all images (3)Free text

Figure 1
Figure 2
Figure 3

Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

Publication Types

MeSH Terms

Substances

Secondary Source ID

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk